RBM39 and hepatocellular carcinoma: In patients with hepatocellular carcinoma, RBM39 was first identified as an autoantigen whose overexpression reduced tumour angiogenesis and growth and inhibited v‐Rel‐mediated lymphocyte transformation.19, 20, 21